Key Points
- CEO Amit Kumar bought 3,000 Anixa Biosciences shares at an average price of $3.73, investing $11,190 and increasing his direct ownership by 0.47% to 643,812 shares.
- Kumar has made several additional purchases recently, including 21,000 shares in June and 5,000 shares on July 20, signaling continued insider buying.
- ANIX shares opened at $3.52, while analysts maintain a “Moderate Buy” consensus with an average price target of $8.50; the company reported a quarterly loss of $0.07 per share, beating estimates.
Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar bought 3,000 shares of the stock in a transaction that occurred on Friday, July 24th. The stock was bought at an average price of $3.73 per share, with a total value of $11,190.00. Following the completion of the purchase, the chief executive officer directly owned 643,812 shares in the company, valued at $2,401,418.76. This represents a 0.47% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.
Amit Kumar also recently made the following trade(s):
- On Monday, July 20th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.46 per share, for a total transaction of $17,300.00.
- On Monday, July 27th, Amit Kumar acquired 3,188 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.37 per share, with a total value of $10,743.56.
- On Monday, July 27th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.44 per share, for a total transaction of $17,200.00.
- On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.04 per share, with a total value of $15,200.00.
- On Friday, June 12th, Amit Kumar purchased 21,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $2.50 per share, with a total value of $52,500.00.
Anixa Biosciences Stock Performance
Shares of ANIX opened at $3.52 on Wednesday. The stock has a 50-day moving average of $2.93 and a two-hundred day moving average of $2.92. The stock has a market cap of $119.75 million, a P/E ratio of -11.35 and a beta of 0.59. Anixa Biosciences Inc has a one year low of $2.32 and a one year high of $5.46.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. Analysts predict that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of ANIX. Marshall Wace LLP purchased a new stake in Anixa Biosciences in the 2nd quarter worth approximately $39,000. NewEdge Advisors LLC purchased a new position in shares of Anixa Biosciences during the 2nd quarter valued at approximately $33,000. Jane Street Group LLC lifted its stake in shares of Anixa Biosciences by 37.2% in the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company's stock valued at $138,000 after purchasing an additional 11,340 shares during the period. Benjamin Edwards Inc. acquired a new position in shares of Anixa Biosciences in the 2nd quarter valued at $37,000. Finally, Vanguard Group Inc. grew its position in Anixa Biosciences by 2.1% during the third quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company's stock valued at $4,694,000 after buying an additional 29,436 shares during the period. 29.13% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on ANIX shares. Citigroup reiterated a "buy" rating on shares of Anixa Biosciences in a report on Friday, June 12th. HC Wainwright restated a "buy" rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Anixa Biosciences in a report on Wednesday, June 17th. Zacks Research upgraded shares of Anixa Biosciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 21st. Finally, D. Boral Capital reissued a "buy" rating and set a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Anixa Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $8.50.
Get Our Latest Stock Report on Anixa Biosciences
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
